Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Core 2 O-glycan antigen
- Molecular classification
- Other (glycan structure/epitope), Carbohydrate antigen, Glycosylation motif, Not a protein family, receptor, or enzyme
01
Overview
Core 2 O-glycan antigen is a structural motif in mucin-type O-glycoproteins, consisting of a GlcNAcβ1-6GalNAc linkage attached to serine or threonine residues on proteins. It acts as an extended branching structure built upon Core 1, predominantly found in tissues with high O-glycosylation (intestine, immune cells). Core 2 O-glycans play essential roles in mediating cell-cell interactions, regulating immune responses through selectin ligand formation, and influencing protein stability and trafficking. They are implicated in cancer and inflammation, as changes in Core 2 structure and density can alter immune cell behavior and malignant potential. Additionally, Core 2 O-glycans serve as scaffolds for further carbohydrate modification, such as addition of sialyl-Lewis x, creating functionally important oligosaccharide epitopes. The term "Core 2 O-glycan antigen" therefore refers to a structural glycan epitope rather than a classical drug target or receptor.
- Other names
- Core 2 O-glycanCore 2 structureCore 2 antigen
02
Biological functions
Immune response modulation (acts as scaffold for selectin ligands; involved in leukocyte rolling and inflammation)Cell-cell recognition and adhesionRegulation of protein trafficking and stabilityFormation of selectin ligands (in myeloid cells)Participation in blood group antigen presentation
03
Disease associations
Cancer (altered glycosylation—Core 2 structures can be upregulated in malignancy and impact tumor cell interaction)Inflammation (regulates selectin ligand formation, influencing leukocyte migration)Infection (pathogens may exploit Core 2 O-glycan structures for cell binding and entry)Congenital disorders of glycosylation (can affect Core 2 structure)
04
Safety considerations
No drugs, therefore no direct safety profile; challenges lie in the specificity of antibodies used for detection or researchHigh molecular heterogeneity and context-specific expression challenge attribution of safety risks to this glycan structure
05
Biomarkers
Sialyl-Lewis x on Core 2 O-glycan (may act as biomarker for cancer detection or monitoring inflammation)Tn/T antigens (related mucin-type O-glycan cores used as tumor markers)Altered Core 2 glycosylation in tumors or certain inflammatory conditions
Beyond the preview
Go deeper on Core 2 O-glycan antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Core 2 O-glycan antigen.